Stayble Therapeutics Phase IIb data support effectiveness in treating herniated discs
Stayble Therapeutics AB ("Stayble" or the "Company") today presents further analyses from the Phase IIb study on degenerative disc disease (DDD) and its impact on the Company's other project on lumbar disc herniation (LDH). In patients who received the higher dose of STA363, a statistically significant difference was observed in disc intensity and disc height, which are clear signs of reduced disc volume. These effects should lead to a decrease in the volume of the herniation and, thus, pain reduction in patients with herniated discs.In the ongoing analyses of results from the DDD study, a